Abstract

Traditional stock and flow models have significant limitations when applied to complex and evolving markets, as they get unwieldy when needed to account for segmentation of the market based on patient characteristics, treatment history, patient preferences, or disease stage.

Pharmacoeconomic models are well suited to address limitations associated with stock and flow models, and they can improve the quality of market outlook predictions.

Within the health economics community, there is a wealth of scientific experience and know-how in the development of the analytical frameworks to address a wide range of research questions that also can be used to help improve the quality of forecasting models.